ENTA
Price:
$6.1
Market Cap:
$129.29M
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.[Read more]
Industry
Biotechnology
IPO Date
2013-03-21
Stock Exchange
NASDAQ
Ticker
ENTA
According to Enanta Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 5.21. This represents a change of -8.63% compared to the average of 5.70 of the last 4 quarters.
The mean historical Current Ratio of Enanta Pharmaceuticals, Inc. over the last ten years is 15.70. The current 5.21 Current Ratio has changed 3.22% with respect to the historical average. Over the past ten years (40 quarters), ENTA's Current Ratio was at its highest in in the December 2016 quarter at 34.84. The Current Ratio was at its lowest in in the June 2024 quarter at 4.92.
Average
15.70
Median
14.55
Minimum
5.21
Maximum
29.43
Discovering the peaks and valleys of Enanta Pharmaceuticals, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 109.43%
Maximum Annual Current Ratio = 29.43
Minimum Annual Increase = -61.48%
Minimum Annual Current Ratio = 5.21
Year | Current Ratio | Change |
---|---|---|
2024 | 5.21 | -22.60% |
2023 | 6.73 | -35.57% |
2022 | 10.45 | 18.49% |
2021 | 8.82 | -51.23% |
2020 | 18.08 | 1.74% |
2019 | 17.77 | -25.12% |
2018 | 23.74 | 109.43% |
2017 | 11.33 | -61.48% |
2016 | 29.43 | 15.61% |
2015 | 25.45 | 11.88% |
The current Current Ratio of Enanta Pharmaceuticals, Inc. (ENTA) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
7.47
5-year avg
9.86
10-year avg
15.70
Enanta Pharmaceuticals, Inc.’s Current Ratio is less than Monte Rosa Therapeutics, Inc. (6.03), less than Design Therapeutics, Inc. (34.61), less than Werewolf Therapeutics, Inc. (10.10), less than Ikena Oncology, Inc. (15.32), greater than Stoke Therapeutics, Inc. (5.09), less than Crinetics Pharmaceuticals, Inc. (16.38), greater than Inhibrx Biosciences, Inc. (4.70), less than Merus N.V. (8.32), less than Lyell Immunopharma, Inc. (13.43), less than Kronos Bio, Inc. (8.32), less than Century Therapeutics, Inc. (10.39), less than Edgewise Therapeutics, Inc. (26.35), less than C4 Therapeutics, Inc. (6.31), less than Mineralys Therapeutics, Inc. (8.55), less than Cullinan Oncology, Inc. (24.46), less than Theseus Pharmaceuticals, Inc. (29.93), less than Revolution Medicines, Inc. (14.24),
Company | Current Ratio | Market cap |
---|---|---|
6.03 | $433.13M | |
34.61 | $359.54M | |
10.10 | $68.63M | |
15.32 | $73.83M | |
5.09 | $599.59M | |
16.38 | $5.00B | |
4.70 | $209.76M | |
8.32 | $2.90B | |
13.43 | $179.07M | |
8.32 | $57.32M | |
10.39 | $87.15M | |
26.35 | $2.80B | |
6.31 | $273.18M | |
8.55 | $637.04M | |
24.46 | $714.45M | |
29.93 | $181.50M | |
14.24 | $8.09B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Enanta Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Enanta Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is Enanta Pharmaceuticals, Inc.'s Current Ratio?
How is the Current Ratio calculated for Enanta Pharmaceuticals, Inc. (ENTA)?
What is the highest Current Ratio for Enanta Pharmaceuticals, Inc. (ENTA)?
What is the 3-year average Current Ratio for Enanta Pharmaceuticals, Inc. (ENTA)?
What is the 5-year average Current Ratio for Enanta Pharmaceuticals, Inc. (ENTA)?
How does the current Current Ratio for Enanta Pharmaceuticals, Inc. (ENTA) compare to its historical average?